A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma

In a phase II study, 43 renal cell carcinoma patients were treated with individualised doses of ABR-214936; a fusion of a Fab recognising the antigen 5T4, and Staphylococcal enterotoxin A. Drug was given intravenously on 4 consecutive days, treatment was repeated 1 month later. Treatment was associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaw, D M, Connolly, N B, Patel, P M, Kilany, S, Hedlund, G, Nordle, Ö, Forsberg, G, Zweit, J, Stern, P L, Hawkins, R E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360042/
https://www.ncbi.nlm.nih.gov/pubmed/17285137
http://dx.doi.org/10.1038/sj.bjc.6603567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360042/
https://www.ncbi.nlm.nih.gov/pubmed/17285137
http://dx.doi.org/10.1038/sj.bjc.6603567

Ejemplares similares